LBA2 Sintilimab plus bevacizumab biosimilar vs sorafenib as first-line treatment for advanced hepatocellular carcinoma (ORIENT-32)2

ORIENT-32 is a randomized, open-label, multi-center phase II/III study to evaluate the efficacy and safety of sintilimab (anti-PD-1 antibody) plus a bevacizumab biosimilar (anti-VEGF antibody), versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HCC). The phase II part has demonstrated an acceptable safety of this combination. Here we report the result of phase III part (NCT03794440). Patients (pts) with unresectable...